Israele - ebraico - Ministry of Health

teva israel ltd - fingolimod as hydrochloride - קפסולות - fingolimod as hydrochloride 0.5 mg - fingolimod

Israele - ebraico - Ministry of Health

rafa laboratories ltd - fingolimod as hydrochloride - קפסולות - fingolimod as hydrochloride 0.5 mg - fingolimod

Israele - ebraico - Ministry of Health

dexcel ltd, israel - ingenol mebutate - ג'ל - ingenol mebutate 150 mcg/g - ingenol mebutate

Israele - ebraico - Ministry of Health

dexcel ltd, israel - ingenol mebutate - ג'ל - ingenol mebutate 500 mcg/g - ingenol mebutate

Israele - ebraico - Ministry of Health

bristol - myers squibb, israel - atazanavir as sulfate - קפסולות - atazanavir as sulfate 300 mg - atazanavir

Israele - ebraico - Ministry of Health

megapharm ltd - tirbanibulin - משחה - tirbanibulin 10 mg - tirbanibulin

Israele - ebraico - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 2 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Israele - ebraico - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 5 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Israele - ebraico - Ministry of Health

megapharm ltd - nitisinone - קפסולה קשיחה - nitisinone 10 mg - nitisinone - nitisinone - treatment of patients with confirmed diagnosis of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine

Israele - ebraico - Ministry of Health

novartis israel ltd - lapatinib as ditosylate monohydrate - טבליות מצופות פילם - lapatinib as ditosylate monohydrate 250 mg - protein kinase inhibitors - tykerb is indicated for the treatment of adult patients with breast cancer, whose tumours overexpress her2 (erbb2);• in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting (see section 5.1).• tykerb is indicated in combination with letrozole for the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer that overexpresses the her2 receptor for whom hormonal therapy is indicated. tykerb in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.